Targeted treatment of AML using T cell recruiting antibody constructs
Targeted treatment of AML using T cell recruiting antibody constructs
PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer
The potential of PARP inhibitors in new cancer groups and in combination with other treatments
Are PARP inhibitors a new standard of care option for MBC patients?
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Cutting-edge cancer care at the Miami Cancer Institute
Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia
Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities
ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL
Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia
Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM
Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry